Biotech company Regeneron (NASDAQ: REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.
Regeneron beat analysts’ revenue expectations by 1% last quarter, reporting revenues of $3.79 billion, up 10.3% year on year. It was a strong quarter for the company, with a decent beat of analysts’ EPS estimates.
Is Regeneron a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Regeneron’s revenue to grow 3.1% year on year to $3.24 billion, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $8.48 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Regeneron has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3.1% on average.
Looking at Regeneron’s peers in the biotechnology segment, some have already reported their Q1 results, giving us a hint as to what we can expect. AbbVie delivered year-on-year revenue growth of 2.3%, missing analysts’ expectations by 2.5%, and Gilead Sciences reported flat revenue, falling short of estimates by 2.1%. Gilead Sciences traded down 2.7% following the results.
Read our full analysis of AbbVie’s results here and Gilead Sciences’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.6% on average over the last month. Regeneron is down 4.9% during the same time and is heading into earnings with an average analyst price target of $850.21 (compared to the current share price of $603.21).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
